RecruitingNCT05736302
Validating a New Machine-Learned Accelerometer Algorithm Using Doubly Labeled Water
Sponsor
University of Wisconsin, Milwaukee
Enrollment
125 participants
Start Date
Mar 14, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to validate previously developed physical function-clustered specific machine-learned accelerometer algorithms to estimate total daily energy expenditure (TDEE) in individuals with general movement and functional limitations.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- must be 18+ years of age
- be able to ambulate on own, unassisted, on a regular basis
- speak and read English
- must have access to a working smart phone and a computer with internet access
Exclusion Criteria11
- wheelchair reliant
- assistive walking device reliant (cannot walk for at least 50 feet without an assistive device)
- diagnosed uncontrolled hypertension (above 160/100 mgHg)
- diagnosed cognitive impairment or inability to follow study procedures such as Alzheimer's disease or dementia
- cannot take metabolic altering medications
- cannot be pregnant
- cannot be breastfeeding
- cannot use supplemental oxygen
- cannot completed required study activities for any reason
- cannot have a resting heart rate > 100 bpm or a resting blood pressure > 160 mgHg during Visit 1
- cannot weigh more than 450 lbs
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERDoubly-Labeled Water
All eligible participants will receive a dose of doubly-labeled water.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05736302
Related Trials
Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System - RAPID for CNS
NCT065536254 locations
Botulinum Toxin for the Treatment of Involuntary Movement Disorders
NCT000012081 location
Non-invasive BCI-controlled Assistive Devices
NCT051831521 location
Effects of Targeted Temporal Interference Stimulation of Cerebellar Nuclei on Tremor and Gait Disturbance in Parkinson's Disease Patients
NCT073844421 location
A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications
NCT055391965 locations